Boomray Co. Ltd. has disclosed new conjugates comprising a fibroblast activation protein-α (FAPα) inhibitor covalently linked to radiolabeled chelating agents through a linker. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis, metabolic and neurological disorders.